Innovent Biologics (HKG:1801) granted Roche exclusive global rights to develop, manufacture, and sell IBI3009, a DLL3-targeted antibody-drug conjugate (ADC) candidate.
This collaboration aims to bring treatment options to patients with advanced small-cell lung cancer (SCLC), according to a Thursday filing with the Hong Kong Exchange.
Under the deal, Innovent and Roche will partner on the early-stage development of this ADC candidate, after which Roche will take over full development.
Innovent will receive $80 million in upfront payments and be eligible for up to $1 billion in milestone payments, along with tiered royalties on net sales, the filing stated.
IBI3009 targets DLL3, an antigen significantly overexpressed in certain cancers, particularly SCLC and other neuroendocrine tumors.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。